Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205144 | 0.86 | PDE4A (0.58) | TLR7ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL21076817 | 0.85 | TLR7 (0.59) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23421267 | 0.84 | TLR7 (0.48) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21076606 | 0.84 | TLR7 (0.59) | TLR7ADORA2AADORA2BPDE4APDE4B | |
| SCHEMBL20756629 | 0.83 | TLR7 (0.43) | TLR7ADORA2AADORA2BPDE4APDE4B | |
| SCHEMBL15306090 | 0.83 | NSD2 (0.46) | TLR7ADORA2AADORA2BPDE4APDE4B | |
| SCHEMBL19539581 | 0.82 | TLR7 (0.59) | TLR7ADORA2AADORA2BPDE4APDE4B | |
| SCHEMBL23764385 | 0.81 | PDE8A (0.59) | TLR7ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL2060324 | 0.81 | TLR7 (0.51) | TLR7ADORA2AADORA2B | |
| SCHEMBL7204649 | 0.81 | TLR7 (0.64) | TLR7ADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3450433-B1 | PURINE DERIVATIVES AS TLR7 INHIBITORS FOR TREATING E.G. SYSTEMIC LUPUS ERYTHEMATOSUS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2021-08-18 | — | — | EP | disclosed |
| US-10703755-B2 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703755-B2 | Substituted purine derivative | TLR7, TLR9, TLR1 | TLR7 1/4885ADORA2A 52/4885ADORA2B 56/4885 |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | TLR7, TLR9, TLR1 | TLR7 1/4885ADORA2A 52/4885ADORA2B 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.